CST, 85677S, IL-13RA2/CD213a2 (E7U7B) Rabbit Monoclonal Antibody

Monoclonal Antibody for studying IL13RA2. Validated for WB,IP,IHC,IHC,F. Available in 2 sizes. Highly specific and rigorously validated in-house, IL-13RA2/CD213a2 (E7U7B) Rabbit Monoclonal Antibody (CST #85677) is ready to ship. Product Usage Information Western Blotting: 1:1000 Immunoprecipitation: 1:50 IHC Leica Bond: 1:50 - 1:200 Immunohistochemistry (Paraffin): 1:100 - 1:400 Flow Cytometry (Live): 1:50 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody. For a carrier free (BSA and azide free) version of this product see product # 68588 . Protocol Available protocols: Western Blotting, Immunoprecipitation, IHC Leica Bond, Immunohistochemistry (Paraffin), Flow Cytometry (Live) Specificity / Sensitivity IL-13RA2/CD213a2 (E7U7B) Rabbit Monoclonal Antibody recognizes endogenous levels of total IL-13RA2/CD213a2 protein. This antibody does not cross-react with IL-13RA1 protein. Species Reactivity: Human Source / Purification Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human IL-13RA2/CD213a2 protein. Background Cancer/testis antigens (CTAs) are a family of more than 100 proteins whose normal expression is largely restricted to immune privileged germ cells of the testis, ovary, and trophoblast cells of the placenta. Although most normal somatic tissues are void of CTA expression, due to epigenetic silencing of gene expression, their expression is upregulated in a wide variety of human solid and liquid tumors (1,2). As such, CTAs have garnered much attention as attractive targets for a variety of immunotherapy-based approaches to selectively attack tumors (3). IL-13 receptor alpha-2 (IL-13RA2/CD213a2) is a type-I monomeric transmembrane glycoprotein and component of the IL-4/IL-13 receptor system. Research studies have shown that IL-13RA2 controls IL-13 signaling by serving as a high affinity decoy receptor for IL-13, but not IL-4, in a variety of cellular contexts (4,5). Some studies, however, have suggested that signaling through IL-13RA2 expressed on immunosuppressive myeloid cells facilitates tumor immune evasion through the production of TGF-β (6,7). IL-13RA2 displays a highly restricted expression pattern in normal human tissues, which positions this receptor as a potentially novel therapeutic target for multiple types of solid tumors (8-10). Indeed, research studies have shown that IL-13RA2 is highly over expressed in glioblastomas (11), which has prompted investigation of different IL-13RA2-directed immunotherapies to treat this cancer (12-14). Alternate Names cancer/testis antigen 19; CD213A2; CT19; I13R2; IL-13 receptor subunit alpha-2; IL-13R; IL-13R subunit alpha-2; IL-13R-alpha-2; IL-13RA2; IL13BP; IL13R; IL13RA2; interleukin 13 binding protein; interleukin 13 receptor alpha 2 chain; interleukin 13 receptor subunit alpha 2; interleukin 13 receptor, alpha 2; Interleukin-13 receptor subunit alpha-2; Interleukin-13-binding protein Specification REACTIVITY: H SENSITIVITY: Endogenous MW (kDa): 55, 65 Source/Isotype: Rabbit IgG